CLC Number:
[1] 冯钰,黄振,孙永琨,等.肝癌患者常见药物治疗相关不良反应互联网管理专家指导意见[J].肝癌电子杂志,2021,8(2):16-22. [2] Lin SM, Lu SN, Chen PT, et al.HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int,2017,11(2):199-208.DOI:10.1007/s12072-016-9774-x. [3] Chu D, Lacouture ME, Fillos T, et al.Risk of Hand-Foot Skin Reaction with sorafenib:a systematic review and Meta-analysis[J].Acta Oncol, 2008,47(2):176-186.DOI:10.1080/02841860701765675. [4] Zhao Y, Liu W, Zheng L, et al.Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis[J]. J Gastrointest Oncol,2023,14(6):2536-2548. DOI:10.21037/jgo-23-651. [5] Yamashita T, Kudo M, Ikeda K, et al.REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset[J]. J Gastroenterol, 2020,55(1):113-122. DOI:10.1007/s00535-019-01642-1. [6] Xie Y, Wu H, He Y, et al.Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer[J]. Cell Death Dis, 2024, 15(2):110.DOI:10.1038/s41419-024-06493-0. [7] Chanprapaph K, Rutnin S, Vachiramon V.Multikinase inhibitor-induced Hand-Foot Skin Reaction: a review of clinical presentation, pathogenesis, and management[J]. Am J Clin Dermatol, 2016,17(4):387-402.DOI:10.1007/s40257-016-0197-1. [8] Komatsu H, Yagasaki K, Hirata K, et al.Unmet needs of cancer patients with chemotherapy-related Hand-Foot Syndrome and targeted therapy-related Hand-Foot Skin Reaction: a qualitative study[J].Eur J Oncol Nurs,2019,38:65-69. DOI:10.1016/j.ejon.2018.12.001. [9] Takayasu K, Arii S, Ikai I, et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J]. Gastroenterology,2006,131(2):461-469. DOI:10.1053/j.gastro.2006.05.021. [10] Ogasawara S, Kanai F, Obi S, et al.Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int,2011, 5(3):850-856. DOI:10.1007/s12072-010-9249-4. [11] 周晨,刘家成,石钦,等. 肝癌分子靶向药物及免疫抑制剂治疗的研究现状及进展[J].中华介入放射学电子杂志,2019,7(3):243-250. [12] Sato-Sano M,Cury-Martins J,Macarenco R,et al.Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib[J]. J Dtsch Dermatol Ges,2018,16(12):1486-1489.DOI:10.1111/ddg.13704 . [13] Williams LA, Ginex PK, Ebanks gL Jr, et al. ONS Guidelines for cancer treatment-related skin toxicity[J]. Oncol Nurs Forum, 2020, 47(5):539-556. DOI:10.1188/20.ONF.539-556. [14] Braghiroli CS, Ieiri R, Ocanha JP,et al.Do you know this syndrome? Hand-Foot Syndrome[J].An Bras Dermatol,2017,92(1):131-133. DOI:10.1590/abd1806-4841.20174602. [15] Blum JL, Jones SE, Buzdar AU, et al.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol,1999,17(2):485-493. DOI:10.1200/JCO.1999.17.2.485. [16] Sibaud V, Dalenc F, Chevreau C, et al.HFS-14, a specific quality of life scale developed for patients suffering from Hand-Foot Syndrome[J]. Oncologist, 2011, 16(10):1469-1478. DOI:10.1634/theoncologist.2011-0033. [17] Anderson RT, Keating KN, Doll HA, et al.The Hand-Foot Skin Reaction and Quality of Life Questionnaire: an assessment tool for oncology[J].Oncologist, 2015,20(7):831-838. DOI:10.1634/theoncologist.2014-0219. [18] 于然, 娄彦妮, 贾立群. 手足皮肤反应患者生活质量量表汉化及信效度分析[J].中国中西医结合皮肤性病学杂志, 2020, 19(2):142-144. [19] Finlay AY,Khan GK.Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994, 19(3):210-216. DOI:10.1111/j.1365-2230.1994.tb01167.x. [20] 赵德华,王继生,楚明明,等.抗肿瘤药物引起手足综合征的机制及防治措施[J].中国现代应用药学, 2019, 36(11):1437-1442.DOI:10.13748/j.cnki.issn1007-7693.2019.11.026. [21] Nikolaou V, Syrigos K, Saif MW.Incidence and implications of chemotherapy related hand-foot syndrome[J]. Expert Opin Drug Saf, 2016,15(12):1625-1633. DOI:10.1080/14740338.2016.1238067. [22] Yoshino T, Komatsu Y, Yamada Y,et al.Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations[J]. Invest New Drugs,2015,33(3):740-750. DOI:10.1007/s10637-014-0154-x. [23] 李苗,朱映霞,段相会.卡瑞利珠单抗联合甲磺酸阿帕替尼、替吉奥治疗中晚期原发性肝癌的临床观察[J].中国医药指南, 2023, 21(22):22-25.DOI:10.15912/j.cnki.gocm.2023.22.009. [24] Belum VR, Wu S, Lacouture ME.Risk of Hand-Foot Skin Reaction with the novel multikinase inhibitor regorafenib: a Meta-analysis[J]. Invest New Drugs, 2013, 31(4):1078-1086. DOI:10.1007/s10637-013-9977-0. [25] Belum VR, Serna-Tamayo C, Wu S, et al.Incidence and risk of Hand-Foot Skin Reaction with cabozantinib, a novel multikinase inhibitor: a Meta-analysis[J]. Clin Exp Dermatol,2016,41(1):8-15. DOI:10.1111/ced.12694. [26] Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced Hand-Foot Syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management[J]. J Am Acad Dermatol,2014,71(4):787-794. DOI:10.1016/j.jaad.2014.03.019. [27] Nonomiya Y,Yokokawa T, Kawakami K, et al.Regorafenib-induced Hand-Foot Skin Reaction is more severe on the feet than on the hands[J]. Oncol Res, 2019, 27(5):551-556. DOI:10.3727/096504018X15291727589740. [28] Mahon SM, Carr E.Skin toxicities: common side effect[J]. Clin J Oncol Nurs,2021,25(6):32. DOI:10.1188/21.CJON.S2.32. [29] Lacouture ME.Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer[J]. Cancer Nurs,2007,30(4 Suppl 1):S17-S26. DOI:10.1097/01.NCC.0000281758.85704.9b. [30] Székely H, Tóth LM, Rancz A, et al.Anti-tumor necrosis factor alpha versus corticosteroids: a 3-fold difference in the occurrence of venous thromboembolism in inflammatory bowel disease-a systematic review and Meta-analysis[J]. J Crohns Colitis,2024,18(5):773-783.DOI:10.1093/ecco-jcc/jjad193. [31] Lien RY, Tung HH, Wu SL,et al.Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study[J]. Cancer Rep (Hoboken),2022,5(7):e1532.DOI:10.1002/cnr2.1532. [32] 王容,王超,孙雪蓉,等.硅基修复材料在靶向药物治疗肠道恶性肿瘤病人并发皮肤毒性反应中的应用[J].循证护理,2021,7(7):987-989. [33] 杨渺. 盐酸多柔比星脂质体引起手足综合征的护理[J]. 中国社区医师, 2020, 36(2):149-150. [34] 童竹月, 王彬彬. 手足综合征的最新研究进展[J]. 浙江临床医学, 2017, 19(3): 581-583. [35] Qiu J, Chen M, Liu J, et al.The skin-depigmenting potential of Paeonia lactiflora root extract and paeoniflorin: in vitro evaluation using reconstructed pigmented human epidermis[J]. Int J Cosmet Sci,2016,38(5):444-451. DOI:10.1111/ics.12309. [36] 邓博,彭艳梅,崔慧娟,等.外用中药防治靶向药物皮肤毒性反应的网络药理分析[J].中华中医药学刊, 2019,37(5):1054-1057.DOI:10.13193/j.issn.1673-7717.2019.05.007. [37] Pei JP, Fan LH, Nan K, et al.HSYA alleviates secondary neuronal death through attenuating oxidative stress, inflammatory response, and neural apoptosis in SD rat spinal cord compression injury[J]. J Neuroinflammation, 2017,14(1):97.DOI:10.1186/s12974-017-0870-1. [38] 周琴,周国芳,董良,等.中药熏洗治疗抗肿瘤靶向药相关性手足综合征临床观察[J].浙江中医杂志,2020,55(6):431-432.DOI:10.13633/j.cnki.zjtcm.2020.06.026. [39] 陈佳露, 邵田娱, 张瑶,等. 中药手足宁方外用治疗阿帕替尼所致3级手足皮肤反应的临床研究[J]. 中国中西医结合杂志, 2023, 43(3):298-302. [40] Yu R, Wu X, Jia L, et al.Effect of Chinese herbal compound lc09 on patients with capecitabine-associated Hand-Foot Syndrome: a randomized, double-blind, and parallel-controlled trial[J].Integr Cancer Ther,2020,19:1534735420928466.DOI:10.1177/1534735420928466. [41] 中国中医药信息学会外治分会.中药熏洗(浴)疗法临床外用技术规范(草案)[J]. 中国实验方剂学杂志, 2020,26(9):85-89. DOI:10.13422/j.cnki.syfjx.20200153. [42] 江晓林,杨镇洲.金银花液湿敷治疗西妥昔单抗致痤疮样皮疹的效果观察[J].中国药房,2015,26(2):243-244. [43] 覃霄燕,李鸿章,王海存,等.五味消毒饮熏洗联合心理疏导综合干预阿帕替尼后手足综合征(热毒壅盛)随机平行对照研究[J].实用中医内科杂志,2018,32(8):24-28.DOI:10.13729/j.issn.1671-7813.z20180195. [44] 朱孝娟. 参草手足润肤膏治疗抗肿瘤药物引起手足综合征的随机双盲对照研究[D].北京:中国中医科学院,2015. [45] Andayani Y.Efficacy of Extra Virgin Olive Oil(EVOO) Supplementation on Serum COX-2, Malondialdehyde, TNF-alpha,Hand-Foot Syndrome incidence in patients with capecitabine: NCT06188000[R]. clinicaltrials.gov, 2024[2024-01-01].https://clinicaltrials.gov/study/NCT06188000. [46] Jessa Hospital.Evaluating the effectiveness of photobiomodulation therapy in the management of Hand-Foot Syndrome and Hand-Foot Skin Reaction:a single-arm trial: NCT04979078[R].[2024-01-01].https://clinicaltrials.gov/study/NCT04979078. [47] Chen J, Wang Z.How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs[J]. J Oncol Pharm Pract, 2021, 27(4):919-929.DOI:10.1177/10781552211009291. [48] Ding J, Farah MH, Nayfeh T, et al.Targeted therapy- and chemotherapy-associated skin toxicities: systematic review and Meta-analysis[J]. Oncol Nurs Forum, 2020, 47(5):E149-E160. DOI:10.1188/20.ONF.E149-E160. |
[1] | ZHANG Yi-fan, XU Xiao-xia, WANG Zi-jiao, LIU La-mei, LI Zhen-ying, MAO Zhen-xue. Latent categories of moral courage among nurses in oncology department and its influencing factors [J]. Journal of Nursing, 2024, 31(13): 7-11. |
[2] | LI Li-xiang, LIU Qiong-ling, WAN Chong-hua, WANG Li-ping, LIN Hua-min, ZHU Xiao-jia, CHEN Zhen-fei, LIANG Wen-xin, LI Qi-zhen. Mediating effect of resourcefulness between family resilience and anticipatory grief in patients with advanced lung cancer [J]. Journal of Nursing, 2024, 31(12): 54-58. |
[3] | QIAN Da-di, ZHOU Hong-zhen, WANG Hong-xiao, DENG Shui-juan, LONG Hao. Experience of undergoing gamma knife radiosurgery in patients with intracranial tumor: a qualitative research [J]. Journal of Nursing, 2024, 31(11): 6-11. |
[4] | . [J]. Journal of Nursing, 2024, 31(11): 63-67. |
[5] | . [J]. Journal of Nursing, 2024, 31(10): 33-36. |
[6] | . [J]. Journal of Nursing, 2024, 31(8): 49-54. |
[7] | . [J]. Journal of Nursing, 2024, 31(8): 60-62. |
[8] | CHEN Rui, WANG Mei, TANG Xiao-xia, ZHU Ao-xue, MAO Hui-na. Construction of nursing need protocol for cancer patients receiving immune checkpoint inhibitor therapy based on ERG theory [J]. Journal of Nursing, 2024, 31(7): 1-5. |
[9] | ZHOU Yi-feng, YANG Ji-ping, HU Zheng-zhong, YUAN Hao. Evidence summary for target-oriented blood glucose monitoring in patients undergoing hepatocellular carcinoma resection [J]. Journal of Nursing, 2024, 31(7): 46-50. |
[10] | . [J]. Journal of Nursing, 2024, 31(6): 73-78. |
[11] | DUAN Nai-juan, SUN Li, LI Feng-xia, ZHANG Hui. Construction of participatory art therapy intervention scheme for cervical cancer patients and their spouses based on Dyadic Coping Theory [J]. Journal of Nursing, 2024, 31(5): 7-11. |
[12] | . [J]. Journal of Nursing, 2024, 31(4): 12-16. |
[13] | . [J]. Journal of Nursing, 2024, 31(4): 60-64. |
[14] | SONG Cai-ni, ZHENG Yao, SONG Ying, Liu Li-hua. Translation of Information Concealment Scale for cancer caregiver and its reliability and validity in caregiver of lung cancer patients [J]. Journal of Nursing, 2024, 31(3): 17-20. |
[15] | HAN Shuang-rong, LI Qiu-fang, LUO Hao-yue, YANG Jia-yin, LIU La-mei, WANG Xiao-kai. Potential profile analysis of self-pity in lung cancer patients undergoing chemotherapy and its relationship with despair [J]. Journal of Nursing, 2024, 31(2): 65-69. |
|